Amgen sees rare diseases as ‘fourth pillar’ of growth, driven by pair of 2022 deals

Amgen believes the marketed drugs and pipeline it received via the 2022 takeouts of Horizon and ChemoCentryx now position rare diseases as a “fourth pillar” driving the company’s growth, alongside general medicine, oncology and inflammation.

On an investor call late Thursday, management at Amgen Inc. (NASDAQ:AMGN) outlined expectations for four marketed medicines the company thinks will anchor its rare disease business, and described steps it can take to reach larger patient populations for each...